BioMaxima S.A. primarily manufactures and sells microbiological culture media, as well as supplements, additives and other components of microbiological media for industrial laboratories. In addition, it manufactures diffusion systems for determining drug susceptibility and resistance mechanisms of bacteria and fungi, as well as proprietary diagnostic reagents for testing biochemical parameters of blood and other body fluids. The company also produces rapid tests for the detection of cancer markers, heart attack markers, addictive agents, and, what is important, infectious diseases, including SARS-CoV- 2 infections (antigen tests).
Production of the solutions described above takes place in Lublin, in a plant expanded in 2017 – 2018.
Since 2010 BioMaxima S.A. has been listed on the NewConnect market. The value of the company now debuting on the WSE Main Market is PLN 160,444,800.